A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening

• LDL-C < 6.0 mmol/l

• Triglyceride level < 5.0 mmol/l.

Exclusion Criteria:

• Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.